GOOD READS

NICE Gives Go Ahead To NeoTract’s Groundbreaking UroLift® Prostate Implant That Can Preserve Sexual Function While Offering Urinary Symptom Relief for Millions of Men Affected by Enlarged Prostates

NICE Interventional Procedure Guidance recommends use of prostatic urethral lift implants under “normal arrangements”, the least restrictive classification

PLEASANTON, Calif.--(BUSINESS WIRE)--

NeoTract, Inc., today announced that the UK’s National Institute for Health and Clinical Excellence (NICE) has issued an interventional Procedure Guidance (IPG) approving the UroLift® prostatic lift system for use by UK doctors. The NICE guidance was made following consultations with independent clinical experts and a literature review.

NICE says: “The specialist advisers listed key efficacy outcomes as symptom improvement, improvement in quality of life, reducing or stopping medical therapy [drug therapy], flow improvement, reduction in residual volume and maintenance of sexual and ejaculatory function”.

The NICE IPG means that UK urologists will be able to routinely offer the novel UroLift system to their patients for the first time outside of a clinical trial. The implants are used to treat BPH – a condition caused by an enlarged prostate that begins to obstruct the urinary system. The condition is common, affecting over 40% of men over 50 years of age. BPH symptoms can include urgency, hesitation, straining, dribbling, incomplete emptying (the sensation that the bladder is not empty after urinating), weak urine flow, increased frequency of urination, nocturia, dysuria, and depression resulting in a decreased quality of life.

Patients receiving the UroLift implants report rapid symptomatic improvement, increased urinary flow rates, and preserved sexual function. A significant improvement in Quality of Life for patients was also observed.

Unlike all other permanent treatment options for enlarged prostates that require administration of a spinal or a general anesthetic, the minimally invasive procedure to insert the UroLift implants typically lasts less than an hour, can be carried out under local anesthesia and the patient is able to go home shortly afterwards; the procedure provides significant Improvements without significant downsides and rapid symptom relief.

Mr Neil Barber, Consultant Urologist at Frimley Park Hospital in Surrey says: "Up to now, men with BPH have had two pretty unattractive options - either lifelong drug treatment which is less effective than surgery and has possible side effects including sexual dysfunction, dizziness and headaches, or cutting away parts of the prostate - known as TURP - that is really good at relieving BPH symptoms but has a significant chance of causing permanent dry orgasms and erection problems, and a small chance of developing urinary incontinence. That's not much of a choice. Many men I see in clinic are, understandably, very nervous of having TURP - they may be older but they are men - so whatever their age, they don't want to have an operation which may make them feel less of a man. [The] UroLift [implant] involves retracting and holding back the enlarged prostate so it's gentler than TURP with minimal side effects and it's more effective than drugs. I think it's a really exciting, game changing treatment for men. UroLift [implants] add another option in the armamentarium for some men and is particularly useful in those who want to quickly return to their normal activities and preserve sexual function.”

Urologist Professor Tom McNicholas, who works at the London Clinic and Spire Hospital, Harpenden, as well as in the NHS, has been involved since the start of the project. He says: “Several leading UK surgeons have been using UroLift [implants] for a while now. But there are always difficulties in introducing a new idea and it's reassuring and encouraging that NICE have rigorously assessed [the] UroLift [system treatment] and regard it as both safe and effective. We now hope to use UroLift more widely in the NHS and in the private sector now that NICE has supported it. I have been involved in an NHS pilot research study on the UroLift device because we saw that, aside from the clinical value of the procedure, there were savings and efficiencies that could be achieved by reduced bed stays for this day case procedure - compared to the other, more invasive surgical procedures that are available. I am looking forward to offering it to my NHS patients because UroLift [implants] improve symptoms whilst preserving men's sexual function and these are worthwhile and important outcomes."

Mr Mark Speakman, Consultant Urologist at Taunton's Musgrove Park Hospital, says: “The UroLift [prostatic implant] procedure is a middle ground option for men sitting between drug treatment and surgical transurethral resection of the prostate (TURP). The problem of drug treatment is compliance - men aren't good at taking drugs - and the problem with TURP is the potential side effects, including ejaculatory problems. UroLift [implantation] beats drugs on efficacy and TURP on side effects. Many men have contacted us wanting UroLift, and the announcement will make life easier for British surgeons who want to offer it."

“Receiving NICE interventional procedure guidance is another huge milestone for UroLift® and NeoTract.” commented Dave Amerson, president and CEO of NeoTract. “We are extremely pleased to bring our innovative UroLift System to more physicians and patients in the U.K. as we believe it will make a significant difference in the lives of aging men.”

About BPH and the UroLift System Treatment

BPH is a common condition afflicting more than 500 million ageing men worldwide. Chronic lower urinary tract symptoms (LUTS) associated with BPH can cause loss of productivity and sleep, depression and decreased quality of life. Medication is often the first line therapy but relief can be inadequate and temporary. Side-effects can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts or heats prostate tissue to open the blocked urethra. Although effective, patients have to 'earn' their symptom relief after a difficult period of irritative voiding symptoms and catheterization. Even the 'gold standard' surgery, TURP (Transurethral Resection of the Prostate), can leave patients with permanent side-effects such as urinary incontinence, erectile dysfunction and retrograde ejaculation (dry orgasm).

The UroLift System is designed to open the urethra directly without applying incisions, surgical resection or thermal injury to the prostate. Obstructive prostate lobes are transurethrally pushed aside and small permanent UroLift implants hold the lobes in the retracted position, thus opening the urethra while leaving the prostate intact. Learn more at www.UroLift.co.uk.

The UroLift System is currently available for patients in Europe, Australia and Canada and was FDA approved in 2013.

About NeoTract

NeoTract, Inc. is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent device designed to treat lower urinary tract symptoms (LUTS).

Contact:
Gloucester Road Communications
Amanda Hayhurst
Mobile: +44 0772 0205581
Amanda@amandahayhurst.com

Quiz: How well do you know India's economy?

Question 1

Which of these products is India the world's largest producer of?

Poll Choice Options
  • Wheat
  • Rice
  • Milk
1
2
3
4
5
6
7
8
9
10

Latest News

  • RIL raises $550 mn from Japanese banks

    Mumbai, April 23 (IANS) Mukesh Ambani-led Reliance Industries Ltd (RIL) Wednesday said it has raised $550 million as loan from Japanese banks for part-funding expansion of its petrochemical plant and new gasification unit. "In continuation of the fund raising programme initiated in 2012-13, RIL has tied up Export Credit Agency (ECA) facility of up to USD 550 million co-financed by JBIC (Japan Bank for International Cooperation) and a group of other Japanese banks," the company said in a …

  • Steady PMIs, sluggish China put brakes on European shares

    European shares edged down on Wednesday after three days of gains as data showing China's economy was still stuttering offset some broadly reassuring European purchasing manager index (PMI) numbers. Data compiler Markit's monthly PMI figures, seen as good indicators of future growth, showed that while France's economy was still a drag, Germany was continuing to power the euro zone's recovery. In Asia, China's stock markets had fallen again and the yuan tumbled to 16-month low after a survey …

  • BSE Sensex hits third consecutive record high
    BSE Sensex hits third consecutive record high

    Reuters Market Eye - The BSE Sensex and the Nifty hit record highs for the third consecutive session on Wednesday on the back of gains in blue-chip stocks. The benchmark index hits a record high of 22,901.65. ... …

  • Gold hovers near 2-1/2 month lows
    Gold hovers near 2-1/2 month lows

    Gold was steady but near its lowest in more than two months on Wednesday, with stronger equities denting the metal's safe-haven appeal and outflows from bullion funds showing weak investor appetite. Spot gold was trading flat at $1,283.50 an ounce by 0640 GMT. But if we break that level, we are going to fall to $1,250," said Yuichi Ikemizu, branch manager for Standard Bank in Tokyo. SPDR Gold Trust, the world's largest gold-backed exchange-traded fund and a good measure of investor …

  • Rupee slips below 61 against the dollar

    Mumbai, April 23 (IANS) The Indian rupee fell below 61 against a dollar for the first time in more than a month Wednesday on continued demands for the greenback from oil importers and weakness in other ... …

IN-DEPTH ANALYSIS & INTERVIEWS

  • This might well be India’s biggest Ponzi scam

    It was just too good to be true. Ashok Khital, 45, displays every symptom of a man who knows he's been conned. …

  • India's star studded football league

    High and mighty including Sachin, Salman & Sun Group buy ISL teams …

  • Leaderspeak with Rajesh Janey

    Rajesh Janey, President - India & SAARC, EMC shares many firsts in his life. …

  • Power Hungry

    Gujarat has power round-the-clock. Most other states do not. Why this will matter in the general elections. …

  • Etcetera

    The most keenly watched contest of the current general election will be the one for the Varanasi parliamentary seat, where the Bharatiya Janata Party's prime ministerial hopeful Narendra Modi squares off ... …

  • Economy vs Democracy

    As the country gets election fever, cash comes out of mattresses and turns into liquor, gifts, and food. But it is not bad for the health of the economy, reports Sarika Malhotra from the trenches. …

  • Bracing for Challenges

    Raghuram Rajan is preparing to deal with concerns that may arise when a new government takes charge. …

MARKET MOVERS

  • Most Actives
    Most Actives
    NamePriceChange% Chg
    16.61-0.24-1.42%
    UNITECH.BO
    14.25-0.33-2.26%
    SUZLON.BO
    120.40+7.00+6.17%
    FRL.BO
    67.70+5.75+9.28%
    MANGCHEM.BO
    54.15+1.40+2.65%
    HCLINFO.BO
  • Price % Gainers
    Price % Gainers
    NamePriceChange% Chg
    16.20+2.70+20.00%
    JAGSONPH.BO
    53.50+8.90+19.96%
    RUSHIL.BO
    64.05+9.00+16.35%
    MRPL.BO
    23.55+3.20+15.72%
    KILITCHD.BO
    23.80+2.90+13.88%
    NELCAST.BO
  • Price % Losers
    Price % Losers
    NamePriceChange% Chg
    -10.95-100.00%
    4THGEN.BO
    -17.30-100.00%
    ALFAICA.BO
    -16.81-100.00%
    AMAL.BO
    -11.73-100.00%
    BORAX.BO
    -29.95-100.00%
    BRADYM.BO
  •  
    Recent Quotes
    Symbol Price Change % ChgChart 
    Your most recently viewed tickers will automatically show up here if you type a ticker in the "Enter symbol/company" at the bottom of this module.
    You need to enable your browser cookies to view your most recent quotes.
  • Recent Quotes News

    •  
      Sign-in to view quotes in your portfolios.